About
Dr Anwar Alam completed his Ph.D from Jawaharlal Nehru University, New Delhi. He has more than 15 years of experience in research and 4 years in academic teaching. His area of specialization is Nanoparticle based drug-targeting and Infectious biology. He earlier worked as project Scientist at the ICMR-National Institute of Pathology (ICMR-NIP) and Department of Biochemical Engineering & Biotechnology, IIT-Delhi. He was a member of ICMR-NIP core team for COVID-19 management, where he played key role in establishing central depot for disbursement for COVID-19 kits across India, established labs for sample testing and kit validation. For his exemplary work during COVID-19 pandemic, he was awarded the “COVID warrior” by the ICMR-NIP. He has successfully completed projects funded by GoI Agencies including DBT, DST and ICMR. The main thrust of research in these projects were to explore the epidemiology and multi-drug resistance of TB using Next-generation Sequencing, develop new chemical entities including drug-repurposing and host directed therapies for effective medical interventions. He is part of team that has developed a first-in class drug to target latent TB bacilli. He is currently leading a team of researchers including post-doc Scientists in several extramural projects on Development of Biomarker for screening TB, AI ML based prediction of multi-drug resistance, testing of a low-cost field deployable tool for TB detection and Anti-microbial resistance. He has filed several more than 7 patents that includes medicaments for treatment of infections caused by biofilm forming pathogens and recombinant multi-epitope vaccines.
Dr Anwar has been conferred with Young Scientist award by the Microwave Applications Society of India. He is the Life Member of Indian Immunology Society, Indian Society of Cell Biologist, Indian Association of Cancer Research and member of the Editorial Board of the Frontiers Journal and Nature Journals.